Jeena Sikho Lifecare moves up on incorporating subsidiary company
Jeena Sikho Lifecare is currently trading at Rs. 364.00, up by 1.60 points or 0.44% from its previous closing of Rs. 362.40 on the BSE.
The scrip opened at Rs. 369.20 and has touched a high and low of Rs. 369.20 and Rs. 356.70 respectively. So far 5048 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 809.45 on 09-Feb-2026 and a 52 week low of Rs. 315.60 on 06-Nov-2026.
Last one week high and low of the scrip stood at Rs. 369.20 and Rs. 315.60 respectively. The current market cap of the company is Rs. 4498.67 crore.
The promoters holding in the company stood at 63.67%, while Institutions and Non-Institutions held 5.03% and 31.30% respectively.
Jeena Sikho Lifecare has successfully incorporated a subsidiary company under the name ‘Ayugenomics’ on November 11, 2026 in India, under the provisions of the Companies Act, 2013. The company shall hold 60% of the equity share capital of Ayugenomics, comprising 30,000 equity shares of Rs 10 each. The new entity has been incorporated to carry on the business of research, development, testing, diagnostics and clinical services that combine genomics and allied omics sciences with Ayurveda and other AYUSH systems of medicine. This includes developing genomics-based panels, tests and software, clinical decision-support and artificial intelligence platforms, and clinical databases and registries.
It also includes conducting clinical studies and evidence-generation programmes; developing, validating, manufacturing, licensing and commercialising evidence-based herbal nutraceutical and botanical products and treatment protocols; and offering wellness, preventive-health, training and certification programmes. The company will work with hospitals, government and state programmes and national and international institutions, including in Japan and other overseas markets. It will seek patents, regulatory approvals and registrations in India and abroad, including CDSCO and the USFDA, and will own and commercialise the intellectual property created by the company.
